Feedback
Settings

Settings

Goto Application

1. WO2021028632 - PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE

Submit observation
PermaLink
Publication Number WO/2021/028632
Publication Date 18.02.2021
International Application No. PCT/FR2020/051430
International Filing Date 04.08.2020
IPC
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 9/107 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
A61K 31/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 47/10 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols ; Poloxamers; PEG/POE alkyl ethers
A61K 47/26 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
CPC
A61K 31/192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
192having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
A61K 31/196
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
196the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/381
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
A61K 31/405
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 47/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Applicants
  • SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC [FR]/[FR]
Inventors
  • BULCOURT, Catherine
  • DENIS, Alice
  • SIGURANI, Séverine
Agents
  • LAIGNEAU, Amandine
Priority Data
FR190911709.08.2019FR
Publication Language French (FR)
Filing Language French (FR)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR TOPICAL USE THAT IS IN THE FORM OF A DISPERSED PHASE BASED ON AT LEAST ONE SHORT DIOL IN A CONTINUOUS FATTY PHASE AND COMPRISING AT LEAST ONE ANTI-INFLAMMATORY SUBSTANCE
(FR) COMPOSITION PHARMACEUTIQUE A USAGE TOPIQUE SE PRESENTANT SOUS LA FORME D'UNE PHASE DISPERSEE A BASE D'AU MOINS UN DIOL COURT DANS UNE PHASE GRASSE CONTINUE ET COMPRENANT AU MOINS UNE SUBSTANCE ANTI-INFLAMMATOIRE
Abstract
(EN)
Pharmaceutical composition for topical use (E1) comprising a gelled phase (A1) dispersed in a continuous phase (A2), said pharmaceutical composition (E1) comprising: a gelled phase (A1) comprising at least one anti-inflammatory substance (Al) and at least one diol having from three to eight carbon atoms and represented either by formula (la): Ra 1-(Rb 1)(OH)-(OH)(Rc 1)(Rd1) (Ia), wherein each of the Ra1, Rb1, Rc1 and Rd1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having from one to five carbon atoms, or by formula (lb): Ra 1-C(Rb 1)(OH)-[C(Re 1)(Rf1)]t-C(OH)(Rc 1)(Rd 1) (lb), wherein t is equal to one, two or three, each of the Ra 1, Rb 1, Rc 1 Rd 1, Re 1 and Rf 1 radicals represent, independently of one another, a hydrogen atom or saturated aliphatic radical having from one to five carbon atoms, it being understood that at least one of the Ra 1 or Rb 1 radicals and/or at least one of the Rc 1 or Rd 1 radicals do not represent a hydrogen atom, a fatty phase (A2) comprising at least one oil and an emulsifying system (S) comprising a combination of at least one emulsifying surfactant (S1) and at least one emulsifying surfactant (S2).
(FR)
Composition pharmaceutique à usage topique se présentant sous la forme d'une phase dispersée à base d'au moins un diol court dans une phase grasse continue et comprenant au moins une substance anti-inflammatoire Composition pharmaceutique à usage topique (E1) comprenant une phase gélifiée (A1) dispersée dans une phase continue (A2), ladite composition pharmaceutique (E1) comprenant: une phase gélifiée (A1) comprenant au moins une substance anti-inflammatoire (Al) et au moins un diol comportant de trois à huit atomes de carbone et représenté soit par la formule (la) : Ra1-(Rb1)(OH)-(OH)(Rc1)(Rd1) (Ia), dans laquelle chacun des radicaux Ra1, Rb1, Rc1 et Rd1 représentent indépendamment les uns des autres, un atome d'hydrogène ou radical aliphatique saturé comportant de un à cinq atomes de carbone, soit par la formule (lb) : Ra1-C(Rb1)(OH)-[C(Re1)(Rf1)]t-C(OH)(Rc1)(Rd1) (lb), dans laquelle t est égal à un, deux ou trois, chacun des radicaux Ra1, Rb1, Rc1 Rd1, Re1 et Rf1 représentent indépendamment les uns des autres, un atome d'hydrogène ou radical aliphatique saturé comportant de un à cinq atomes de carbone, étant entendu que l'un au moins des radicaux Ra1ou Rb1 et/ou l'un au moins des radicaux Rc1 ou Rd1 ne représentent pas un atome d'hydrogène, une phase grasse (A2) comprenant au moins une huile et un système émulsionnant (S) comprenant une combinaison d'au moins un agent tensioactif émulsionnant (S1) et d'au moins un agent tensioactif émulsionnant (S2).
Latest bibliographic data on file with the International Bureau
# -